Compared to other vaccine and protein production technologies, the strengths of the PER.C6® cell line lie in its excellent safety profile, scalability and productivity under serum-free culture conditions.   Easy access to extensive PER.C6® cell line expertise, including technical services, process development and seamless transfer to large scale GMP manufacturing, give partners a head start in the manufacturing of clinical trial material.

The PER.C6® cell line performs extremely well in a wide variety of culture formats, processes and media.   The PER.C6® cell line is the best documented cell line to date. Its extensive Biologics Master File at the US FDA can be cross-referenced by licensees, resulting in simplification and acceleration of the IND filing and approval process.